Search clinical trials for: serine

Total 1583 results

University of Florida

Completed

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

Coronary Artery Disease

United States
Samsung Medical Center

Completed

Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

Femur Head Necrosis | Osteoarthritis, Hip | Femoral Neck Fractures
Hospital Universitari Vall d'Hebron Research Institute
VITAE NATURAL NUTRITION, S.L.

Completed

Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. (ReConnect)

Chronic Fatigue Syndrome

Spain
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Switching Study From Warfarin to Rivaroxaban

Venous Thrombosis

Germany
Deutsches Herzzentrum Muenchen

Terminated

Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation (Dabi-ADP-2)

Atherosclerosis | Atrial Fibrillation | Coronary Heart Disease | Acute Coronary Syndrome

Germany
Odense University Hospital

Completed

Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation

Atrial Fibrillation

Denmark
John H. Stroger Hospital
Cook County Hospital

Completed

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study (ARC)

Stroke | Atrial Fibrillation | Bleeding | Thrombo-embolism

United States
Italian Society of Invasive Cardiology
Eustrategy

Unknown

Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)

STEMI | Acute Coronary Syndromes | NSTEMI

Italy
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (RECORD 2)

Venous Thromboembolism | Prevention

Denmark, Italy, China, Indonesia, Colombia, Portugal, United States, Australia, Korea, Republic of, Taiwan, Canada, Estonia, New Zealand, Brazil, Mexico, South Africa, Peru, United Kingdom, Latvia, India, Lithuania, Sweden, Norway
CSL Behring

Completed

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema | Alpha1-proteinase Inhibitor Deficiency

Australia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
AZ Sint-Jan AV
Onze Lieve Vrouw Hospital

Completed

Dose-finding of Rivaroxaban in Hemodialysis

Chronic Renal Failure

Belgium
Children's Hospital Los Angeles

Withdrawn

Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO

Neonates on ECMO

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Renal Insufficiency, Chronic

Netherlands
Beijing Anzhen Hospital

Unknown

Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Atrial Fibrillation

China
The Hospital for Sick Children

Completed

Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

Cardiopulmonary Bypass

Canada
National Institute of Allergy and Infectious Diseases...
Juvenile Diabetes Research Foundation; Immune Tolerance Network (ITN)

Withdrawn

A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II (RETAIN)

Diabetes Mellitus, Type 1

United States
Bayer

Completed

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Atrial Fibrillation

Japan
Bayer

Completed

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

Blood Loss, Surgical

United States, Canada, Puerto Rico
Bayer

Completed

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

Atrial Fibrillation

Japan
Bayer

Completed

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

Atrial Fibrillation

Japan
Green Cross Corporation
Parexel

Completed

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Healthy Volunteers

United States
Bayer

Completed

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Venous Thromboembolism

United States, Canada
Bayer

Terminated

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Blood Loss, Surgical | Postoperative Hemorrhage

Belgium, United States, Sweden, Germany, Netherlands, United Kingdom, France
Bayer

Completed

ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)

Thromboembolism | Prevention

Belgium, Denmark, Austria, Germany, Netherlands, Poland, Sweden, Israel, France, Norway, United Kingdom
Korea University

Unknown

Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

Atrial Fibrillation | Thromboembolism
University Hospital, Grenoble
Celgene Corporation

Unknown

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs (MYELAXAT)

Venous Thromboembolism | Myeloma

France
Bayer

Terminated

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Blood Loss, Surgical

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Spain, United Kingdom
Rabin Medical Center

Unknown

Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke

Ischemic Stroke

Israel
Sanofi

Completed

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome (SEPIA-ACS1)

Coronary Disease

United States, France, Brazil, Poland, Romania, Russian Federation, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, Turkey, Bulgaria, India, Malaysia, Singapore, Slovakia, Taiwan, Czech Republic, Mexico, Argentina, Croatia, Austri... and more
Stony Brook University

Terminated

Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention (STATUS PCI)

Coronary Artery Disease

United States
Herzog Hospital

Completed

Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans (NMDAR)

Healthy
Seoul National University Hospital
Seoul National University Bundang Hospital; Daegu Catholic University Medical... and other collaborators

Unknown

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study (PRAIS)

Ileofemoral Deep Vein Thrombosis

Korea, Republic of
The University of Texas Health Science Center,...

Completed

Argatroban Stroke Treatment - A Pilot Safety Study

Ischemic Stroke

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. (RECORD 4)

Venous Thromboembolism

Poland, United States, India, Denmark, Canada, Sweden, Bulgaria, Israel, Lithuania, Norway, Pakistan, Mexico, Sri Lanka
University of Alberta

Completed

Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke (DATAS)

Transient Ischemic Attack | Minor Ischemic Stroke

Canada
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Venous Thromboembolism

France, Italy, Czech Republic, Canada, Netherlands, Australia, United States, Poland, South Africa, Sweden, Israel, Denmark, Brazil
Bayer

Completed

Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXaHIP-OD)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, Norway, United Kingdom, France
Bayer

Completed

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Venous Thromboembolism

Italy, Spain, Poland, United States, Czech Republic, Canada, Denmark, Netherlands, Belgium, Chile, Slovakia, Hungary, Austria, France, Germany, South Africa, Sweden, Turkey, Colombia, Israel, Mexico, Argentina, Norway, Brazil, Lithuania, ... and more
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Regado Biosciences, Inc.
Icahn School of Medicine at Mount Sinai; The Cleveland Clinic; Parexel; Duke Clinical... and other collaborators

Terminated

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate)

Coronary Artery Disease

United States
Janssen Research & Development, LLC
Bayer

Completed

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Healthy | Renal Insufficiency

United States
Shenyang Northern Hospital

Completed

BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial. (BRIGHT)

Percutaneous Coronary Intervention | Acute Myocardial Infarction

China
Universitaire Ziekenhuizen KU Leuven

Completed

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Reperfusion Injury

Belgium
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

United States, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Chile, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Malaysia, Romania, Russian Federation, Serbia, Turkey, Korea, Republic of, ... and more
Grifols Therapeutics LLC

Completed

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (ChAMP)

Alpha 1-Antitrypsin Deficiency

United States
Duke University
GlaxoSmithKline

Completed

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" (FONDA PK)

Renal Insufficiency

United States
Grifols Therapeutics LLC

Completed

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Alpha 1-Antitrypsin Deficiency

Denmark, Sweden, United Kingdom
Grifols Therapeutics LLC

Completed

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients (CF2)

Cystic Fibrosis
Xijing Hospital

Unknown

Edoxaban for TIA and Acute Minor Stroke

Ischemia | Stroke | Cerebral Infarction

China

Search clinical trials for: serine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations